3.53
Molecular Partners Ag Adr stock is traded at $3.53, with a volume of 424.
It is down -4.59% in the last 24 hours and down -4.85% over the past month.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.
See More
Previous Close:
$3.70
Open:
$3.4101
24h Volume:
424
Relative Volume:
0.05
Market Cap:
$142.52M
Revenue:
$7.80M
Net Income/Loss:
$-69.02M
P/E Ratio:
-1.6485
EPS:
-2.1413
Net Cash Flow:
$-66.61M
1W Performance:
-8.75%
1M Performance:
-4.85%
6M Performance:
-31.59%
1Y Performance:
-55.88%
Molecular Partners Ag Adr Stock (MOLN) Company Profile
Name
Molecular Partners Ag Adr
Sector
Industry
Phone
-
Address
-
Compare MOLN with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
MOLN
Molecular Partners Ag Adr
|
3.53 | 136.44M | 7.80M | -69.02M | -66.61M | -2.1413 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Molecular Partners Ag Adr Stock (MOLN) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Aug-30-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
Aug-29-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
May-25-22 | Upgrade | Credit Suisse | Underperform → Neutral |
Apr-27-22 | Downgrade | Credit Suisse | Neutral → Underperform |
Jul-13-21 | Initiated | Cowen | Outperform |
Jul-12-21 | Resumed | SVB Leerink | Outperform |
View All
Molecular Partners Ag Adr Stock (MOLN) Latest News
Molecular Partners (NASDAQ:MOLN) Stock Price Down 3.4% – Should You Sell? - Defense World
Molecular Partners presents positive data from ongoing Phase 1/2a trial of MP0533 in AML at EHA 2025 - GlobeNewswire Inc.
Walmart, Deere, Applied Materials set to report earnings Thursday By Investing.com - Investing.com Nigeria
Walmart, Deere, Applied Materials set to report earnings Thursday - Investing.com
Ziff Davis Inc (NASDAQ:ZD) Shares Jumped 1.54% In A Week. Can It Continue Rising? - Marketing Sentinel
Molecular Partners' AACR 2025 Breakthroughs: Radio-DARPins and Smart T Cell Engagers Ignite Oncology Potential - AInvest
Can Contango ORE, Inc. (CTGO) Climb 163.28% to Reach the Level Wall Street Analysts Expect? - Yahoo Finance
Here's Why Molecular Partners AG Sponsored ADR (MOLN) Could be Great Choice for a Bottom Fisher - Yahoo Finance
Musk's DOGE Exit Rumors & Weak Q1 Deliveries: How to Play Tesla Now - Yahoo Finance
Why Tractor Supply (TSCO) is a Top Momentum Stock for the Long-Term - Yahoo Finance
TD Cowen maintains Buy on Molecular Partners, target CHF15 - Investing.com India
Molecular Partners reports 2024 annual results - Investing.com India
Wall Street Analysts Think Molecular Partners AG Sponsored ADR (MOLN) Could Surge 80.72%: Read This Before Placing a Bet - Yahoo Finance
Molecular Partners, Orano Med announce presentation of MP0712 data - TipRanks
Molecular Partners: Sellers Have Disappeared, Enterprise Value Below Zero (NASDAQ:MOLN) - Seeking Alpha
US stock market gainers for the last week of April 2022 - Nairametrics
Novartis to push forward with covid drug after positive results - Luxembourg Times
Wall Street Analysts See a 96% Upside in Molecular Partners AG Sponsored ADR (MOLN): Can the Stock Really Move This High? - Yahoo Finance
Citi Appointed as Depositary Bank for Molecular Partners AG’s ADR Programme - Business Wire
Molecular Partners Ag Adr Stock (MOLN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):